President Donald Trump has signed an executive order creating two new bodies dedicated to advancing women's health research in the United States. The move, announced alongside First Lady Melania Trump, establishes a Women's Health Division at the National Institutes of Health (NIH) and a White House Women's Health Task Force, with the stated goal of closing long-standing gaps in medical knowledge and modernising care for women across all stages of life.
Speaking at the signing ceremony, Trump said his administration was committed to ensuring that medical research, diagnosis, prevention, and treatment reflect the highest quality scientific evidence. The executive order directs the new bodies to focus on improving health outcomes for women, a demographic that has historically been understudied in clinical research.
Melania Trump called the moment "transformative" for American women, adding that while previous generations fought for rights, "our generation will fight to discover the cure that will ensure that women can live their lives in health and to the fullest." Her remarks underscored the administration's emphasis on using cutting-edge science, including artificial intelligence and advanced biotechnology, to accelerate progress.
Structure and priorities
The White House Women's Health Task Force, which convened on the day of the signing, is co-chaired by White House chief of staff Susie Wiles and Health Secretary Robert F. Kennedy Jr. Its mandate is to coordinate women's health policy across federal agencies, translate research into evidence-based practice, and identify regulatory reforms that could improve prevention and access to care.
Meanwhile, the NIH's new Women's Health Division is to be established within 90 days. It will coordinate and expand research into conditions that disproportionately or uniquely affect women, improve the inclusion of women and girls in clinical trials, and accelerate the development of better diagnostics and treatments. The division will also hold researchers accountable for accounting for sex-based biological differences in their studies.
Melania Trump outlined five priorities for the initiative: directing research toward diseases that affect women in unique ways; leveraging super intelligence to better understand women's health; speeding up the journey from laboratory discoveries to patient care; ensuring access regardless of financial situation; and addressing previously neglected conditions.
European resonance
While this is a domestic US policy move, its implications extend across the Atlantic. European researchers and policymakers often look to NIH-funded studies as benchmarks, and shifts in US research priorities can influence global medical standards. The initiative also echoes ongoing debates in Europe about gender-specific healthcare, such as the European Trade Union Confederation's recent call for an EU law to protect menopausal women at work, a topic that has gained traction in Brussels and national capitals.
In the UK, the National Health Service has similarly pledged to close the gender health gap, while countries like Sweden and Germany have invested in sex-disaggregated data collection. The US move could accelerate these efforts by providing new data and treatment paradigms that European institutions can adapt.
However, some European health experts caution that the initiative's success will depend on sustained funding and political will. The NIH's budget has faced political battles in Congress, and the new division's effectiveness remains to be seen. Moreover, the task force's co-chair, Robert F. Kennedy Jr., has a history of controversial statements on vaccines and public health, which has raised concerns among some scientists about the direction of US health policy.
Despite these uncertainties, the executive order marks a significant step in acknowledging that women's health has been under-researched for decades. Conditions like endometriosis, autoimmune diseases, and cardiovascular disease in women have historically received less attention than male-centric studies. The new bodies aim to correct that imbalance.
For European observers, the initiative offers a potential model—or a cautionary tale—depending on how it unfolds. As the EU develops its own health research strategies, including the Horizon Europe programme, the transatlantic exchange of ideas and data will be crucial. The US move could spur European institutions to redouble their efforts in women's health, ensuring that no woman is left behind in the pursuit of better health outcomes.
